Overview
- A Monday agreement between the companies gives Cellular Intelligence global rights to Novo Nordisk’s clinical-stage Parkinson’s program.
- Novo Nordisk will take an equity stake in Cellular Intelligence and remains eligible for milestones and royalties, with financial terms undisclosed.
- The therapy is an allogeneic, pluripotent stem cell–derived dopaminergic progenitor now in a Phase 1/2 trial under FDA Fast Track.
- Cellular Intelligence says its AI foundation model will speed clinical development and help scale manufacturing for broader access.
- No new efficacy or safety results accompanied the news, as the program continues in its first-in-human study under an active IND.